The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

May. 08, 2023
Applicant:

Neurotronic, Inc., Plymouth, MN (US);

Inventor:

Lixiao Wang, Henderson, NV (US);

Assignee:

Neurotronic, Inc., Plymouth, MN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 18/14 (2006.01); A61B 18/02 (2006.01); A61B 18/18 (2006.01); A61B 18/24 (2006.01); A61K 49/04 (2006.01); A61M 25/10 (2013.01); A61N 7/00 (2006.01); A61B 18/00 (2006.01); A61F 7/00 (2006.01); A61F 7/12 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01);
U.S. Cl.
CPC ...
A61B 18/1492 (2013.01); A61B 18/0218 (2013.01); A61B 18/18 (2013.01); A61B 18/1815 (2013.01); A61B 18/24 (2013.01); A61K 49/0438 (2013.01); A61M 25/10 (2013.01); A61N 7/00 (2013.01); A61B 2018/00285 (2013.01); A61B 2018/00345 (2013.01); A61B 2018/00482 (2013.01); A61B 2018/00541 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00994 (2013.01); A61B 2018/0212 (2013.01); A61F 2007/0063 (2013.01); A61F 2007/0091 (2013.01); A61F 2007/126 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61M 25/1011 (2013.01); A61M 2025/1052 (2013.01); A61N 2007/0043 (2013.01);
Abstract

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.


Find Patent Forward Citations

Loading…